Indivior (INDV) has seen a significant rise in its stock price, moving up 12 spots to 38th on Barchart’s Top 100 Stocks to Buy list. The company’s share price has surged nearly 200% in the past year, with a large portion of gains in the last three months.

The company’s revenue and adjusted EBITDA projections for 2025 have been raised, now expecting revenue of $1.2 billion and adjusted EBITDA of $410 million. This implies 1% revenue growth and 15% adjusted EBITDA growth over 2024.

Indivior is focused on growing its SUBLOCADE® treatment for opioid use disorder and expanding its market share. With the addition of experienced personnel and cost reductions, the company is poised for growth in 2026 and beyond.

Analysts predict that Indivior will earn $2.86 a share in 2026, with a current P/E ratio of 12.5. All seven analysts covering the stock rate it a Buy, with an average target price of $37.86, indicating potential for further growth.

As Indivior continues to execute its commercialization plans and expand its market presence, there is a strong possibility of increased analyst coverage and higher share prices. The company’s strategic focus on opioid treatments and LAIs positions it for success in the coming years.

Read more at Yahoo Finance: Why This Top 100 Stock to Buy Is Getting Cheaper Even as It Soars Higher